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Oral squamous cell carcinoma (OSCC) is genetically highly heterogeneous, which contributes to the
challenges of treatment. To create an in vitro model that accurately reﬂects this heterogeneity, we
generated a panel of HPV-negative OSCC cell lines. By whole exome sequencing of the lines and matched
patient blood samples, we demonstrate that the mutational spectrum of the lines is representative of
primary OSCC in The Cancer Genome Atlas. We show that loss of function mutations in FAT1 (an atypical
cadherin) and CASP8 (Caspase 8) frequently occur in the same tumour. OSCC cells with inactivating FAT1
mutations exhibited reduced intercellular adhesion. Knockdown of FAT1 and CASP8 individually or in
combination in OSCC cells led to increased cell migration and clonal growth, resistance to Staurosporine-
induced apoptosis and, in some cases, increased terminal differentiation. The OSCC lines thus represent a
valuable resource for elucidating the impact of different mutations on tumour behaviour.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).Introduction
The global annual incidence of head and neck squamous cell
carcinoma (HNSCC) is approximately 600,000, with over 300,000
deaths attributable to the disease each year [1]. HNSCC lesions
frequently recur and metastasize to other locations, contributing to
signiﬁcant morbidity and mortality [2]. Despite improvements in
surgical care and adjuvant therapy, the 5-year survival rate is only
60% in the United States [3].
Previous studies have used next-generation whole exome
sequencing of primary tumours to reveal themutational landscapes
of human HNSCCs and suggest novel oncogenic drivers to target for
potential therapies [4e6]. HNSCC is strikingly heterogeneous at
both the genetic and the cellular level. No single genetic lesion
predominates and patients often develop more than one primary
tumour.
Oral cancer is a subtype of HNSCC, comprising tumours of the lip
and oral cavity. Worldwide, over 250,000 new cases and 125,000r Ireland Ltd. This is an open accesdeaths from oral cancer occurred in 2008 [1]. Approximately 90% of
oral cancers are squamous cell carcinomas (SCCs), arising in the
multilayered epithelia that line themouth and lips. Oral SCC (OSCC)
frequently involves the tongue, and can also occur in the ﬂoor of the
mouth, gingiva, cheek and palate. The two major risk factors for
OSCC are smoking and alcohol consumption [7]. In contrast to
HNSCC of the tonsils and oropharynx, OSCC tends not to be asso-
ciated with HPV infection [8,9]. Despite advances in treatment, the
survival rate for OSCC remains stubbornly low [3].
As in other solid tumours [10,11], the properties of the malig-
nant epithelial cells in HNSCC elicit an immune inﬁltrate and acti-
vation of ﬁbroblasts in the surrounding connective tissue stroma
[1,3,12]. Integrative analysis of the genetic and cellular heteroge-
neity of HNSCC is beginning to reveal new biologically distinct
subtypes of the disease [13], and greater understanding of their
signiﬁcance could inform future therapies. One way to achieve this
is by studying the properties of cells isolated from HNSCC.
Cells can readily be cultured from human oral tumours and
normal oral mucosa, and several well-annotated collections of
HNSCC cells are available [14e16]. However, genetic changes in
individual cell lines have not been compared with control DNAs article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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whether the lines truly reﬂect the genetic heterogeneity of OSCC or
are dominated by mutations acquired during long-term culture.
The value of such lines lies in characterising the biology of genes
that are frequently mutated in OSCC, including NOTCH1, CASP8
(Caspase 8) and FAT1 (an atypical cadherin) [6], which are not
conventional oncogenes/tumour suppressor genes and can poten-
tially have pleiotropic effects on tumour properties. For example,
the association between FAT1 mutation and overall survival in
HNSCC differs according to the HPV status of the tumour [17], and
loss of Caspase 8 not only has cell intrinsic effects [18] but can also
trigger inﬂammation [19]. Furthermore, there is evidence for bio-
logical interactions between FAT1 and Caspase 8, with FAT1 acting
as an antagonist of Caspase 8 in a synthetic lethal screen in cancer
cell lines [20].
In this study, we set out to develop new OSCC lines, discover
which mutations are tumour-acquired and determine whether
they are indeed representative of mutational burden in primary
tumours.We then used the lines to explore the impact of mutations
in CASP8 and FAT1 on cell behaviour.
Materials and methods
Derivation of OSCC lines
Anonymized biopsies of OSCC or normal oral mucosa were collected with
appropriate ethical approval (UK National Research Ethics Service (08/H0306/30).
Cells were isolated and cultured on a feeder layer of J2 3T3 cells in complete FAD
medium as described previously [16].
Whole exome sequencing
Genomic DNA was extracted from OSCC lines (passage 2e4) and patient-
matched blood. Whole exome sequencing was performed by Beijing Genomics
Institute (Hong Kong). Raw image ﬁles were processed by Illumina base calling
Software 1.7 or base calling with default parameters, and the sequences of each
individual were generated as 90 bp paired-end reads. High-quality reads were
aligned against the NCBI human reference genome (hg19) using Burrows-Wheeler
Aligner (v0.5.9) with default parameters. Picard (v1.54) was employed to mark
duplicates and was followed by Genome Analysis Toolkit (v1.0.6076, GATK Indel-
Realigner) to improve alignment accuracy. Putative somatic single nucleotide vari-
ations (SNVs) were predicted by VarScan2.25 with the parameters as “– min-
coverage 5 –min-coverage-normal 5 –min-coverage-tumour 5 –min-var-freq 0.1
–min-freq-for-hom 0.75 –min-avg-qual 0dsomatic-p-value 0.15”. In order to obtain
high conﬁdence somatic SNVs, an in-house pipeline was applied. Somatic InDels
were predicted by GATK SomaticInDelDetector with default parameters. A pipeline
was developed to obtain high conﬁdence somatic InDels; normal and tumour bam
were reused to perform local realignment and germline indels were ﬁltered for high
conﬁdence indels, with normal coverage and tumour coverage no less than 5. High
conﬁdence somatic single nucleotide variants and InDels were annotated using
ANNOVAR. Functional impacts of missense mutations were predicted using SIFT,
PolyPhen2, PhyloP, MutationTaster and LRT annotations.
Prediction of driver genes and pathways
The Oncodrive-fm method was applied, as previously published, to identify
signiﬁcantly mutant genes and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathways [21]. Pathway enrichment analysis was also performed to identify addi-
tional signiﬁcantly mutated KEGG pathways.
KEGG pathway analysis and clustering
Whole exome sequencing data from The Cancer Gene Atlas (TCGA) HNSCC
collection [6] were accessed from cBioPortal.org. KEGG pathway analysis was per-
formed; elog2(P) values were calculated and presented in heat maps created using
GENE-E software (Broad Institute). OncoPrint, mutation diagrams and tests for
mutual exclusivity of genomic alterations were downloaded from cBioPortal.
Quantitative real-time RT-PCR
RNA was harvested using the RNeasy Mini Kit and QIAshredder columns ac-
cording to the manufacturer's instructions (Qiagen). cDNA was synthesized using
SuperScript™ III First-Strand Synthesis SuperMix (Invitrogen). qPCR was performed
using TaqMan Fast Universal PCR Master Mix without AmpErase UNG (Life Tech-
nologies) on the CFX96 Touch Real-Time PCR Detection System (Bio-Rad) with the
following primers: CASP8 (Hs01018151_m1), FAT1 (Hs00170627_m1) and GAPDH
(Hs02758991_g1) as the internal control (Life Technologies). Relative quantiﬁcation
was performed using the 1/DCt or DDCt methods.Transient transfection
SMARTpool ON-TARGETplus CASP8 and FAT1 (GE Healthcare) and Silencer®
Negative Control No. 1 (Thermo Fisher) siRNAs were used. Prior to transfection,
wells were coated with 20 mg/mL Rat Tail Collagen I (Corning) and incubated for
1 h at 37 C. Cells were transfected using either Lipofectamine RNAiMax or Lip-
ofectamine 2000 with Opti-MEM medium (Thermo Fisher). The viability of
transfected cells was conﬁrmed by Trypan Blue exclusion prior to performing cell
behaviour assays.
Colony formation
48 h after transfection, cells were seeded at clonal density in 6-well plates on a
layer of feeders. 10e14 days after seeding, feeders were detached and keratinocytes
were ﬁxed in 10% formalin and stained with a solution of 1% Rhodamine B and 1%
Nile blue. Well images were acquired on the Gel Doc™ XRþ (Bio-Rad). Percent well
area covered by cells was determined using the ColonyArea plugin [22] for ImageJ.
Cell migration assay
24 h after transfection, cells were seeded on collagen-coated well plates in
the Oris™ Cell Migration Assay (Platypus Technologies) and cultured in complete
FAD medium. 24 h after plating, cell seeding stoppers were removed. Phase-
contrast images were acquired for 16e24 h using an IncuCyte® ZOOM (Essen
BioScience). Area closure was quantiﬁed in ImageJ, following the manufacturer's
instructions.
Induction of apoptosis
24 h after transfection, cells were seeded on collagen-coated 96-well plates in
complete FAD medium. 24 h later cells were incubated with varying concentrations
of Staurosporine (1285; Tocris) in complete FAD medium for 4 h at 37 C.
Immunoﬂuorescence staining
Cells were ﬁxed in 4% paraformaldehyde, permeabilized using 0.5% Triton X-100
(Sigma-Aldrich) in PBS and blocked in a solution of 10% fetal bovine serum (Thermo
Fisher), 0.25% gelatin from cold water ﬁsh skin (Sigma-Aldrich) and 0.5% Triton X-
100 in PBS. Cells were incubated overnight at 4 C with the following primary an-
tibodies in blocking buffer: rabbit anti-Ki67 (1:50; ab16667; Abcam), Alexa Fluor®
488 conjugated anti-cleaved Caspase-3 (Asp175) antibody (1:50 in blocking buffer;
9669; Cell Signalling) or mouse anti-transglutaminase 1 (TGM1; clone BC1; 1:500).
Cells were incubated for 1 h at room temperature in blocking buffer with the
following secondary antibodies, as appropriate: Alexa Fluor® 488 goat anti-rabbit
IgG H þ L (1:1000; ab150077; Abcam) or Alexa Fluor® 555 goat anti-mouse IgG
H þ L (1:1000; ab150114; Abcam). Plasma membranes and nuclei were counter-
stainedwith CellMask™Deep Red (1:1000 in PBS; C10046; Thermo Fisher) and DAPI
(1 mg/mL in PBS), respectively, for 1 h at room temperature. Following Caspase-3
labelling cell nuclei were counterstained with DRAQ5™ (5 mM in PBS; 108410;
Abcam). Images were acquired using the Operetta® High-Content Imaging System
(PerkinElmer). Positive nuclear Ki67 and cytoplasmic TGM1 immunostaining were
quantiﬁed using an in-house pipeline on Harmony® software (PerkinElmer), while
Caspase-3 positive cells were quantiﬁed using the “Apoptosis-1” module
(PerkinElmer).
Statistical analyses
Data were analyzed using an unpaired Student's t-test or one-way ANOVA with
Tukey's Multiple Comparison Post Test on GraphPad Prism 5.0b, and a P value of
<0.05 was considered signiﬁcant, unless otherwise noted.
Results
Whole exome sequencing of OSCC lines
We derived multiple low passage polyclonal cell lines from
primary oral squamous cell carcinoma biopsies by culture on a
3T3 J2 feeder layer in order to minimise selection for rapidly
dividing cells [16]. Whole exome sequencing was performed on
16 lines, together with patient-matched blood. We achieved 37-
and 43-fold mean sequence coverage of targeted exonic regions,
with 73 and 77% of loci covered at 20-fold from tumour and
matched blood samples, respectively (Supplementary Fig. S1).
Mutation rates varied from 2.50 to 44.7 mutations/megabase
(mean 16.9 ± 13.5), with 80e1431 somatic mutations per sam-
ple (mean 539 ± 432) (Fig. 1A; Supplementary Table S1). A total
of 8629 single nucleotide variations across 2611 genes were
found, of which 5839 (68%) were synonymous, 2621 (30%)
Fig. 1. Genomic analysis of OSCC lines and TCGA HNSCC tumours. AeC) Somatic mutation rates (A), nucleotides transition and transversion frequencies (B), clinical characteristics
and social histories (C) of cell lines and patients fromwhich they were derived. D) Somatic single nucleotide variants (SNVs) and insertion/deletions (indels) in signiﬁcantly mutated
genes. Genes are ranked in order of signiﬁcance from TCGA (6). E) Unsupervised clustering of TCGA HNSCC samples according to signiﬁcance of mutated KEGG pathways. Rows are
individual tumours; columns are KEGG pathways. OSCC are shown separately from other HNSCC. F) Unsupervised clustering of TCGA OSCC samples ranked according to frequency
of mutated KEGG pathways (descending rank order) in OSCC cell lines. Rows are pathways and columns are individual tumours. (E, F) Colour scale is based on elog2(P) values.)
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splice-site mutations (Supplementary Table S2). Ninety-ﬁve in-
sertions/deletions (indels) were found across 83 genes, of which
36 (43%) and 27 (32.5%) were non-frameshift and frameshift
deletions, respectively. Thirteen (16%) and 19 (23%) were non-
frameshift and frameshift insertions, respectively. The ratio of
nucleotide transitions to transversions ranged from 1.17 to 3.00
(mean 2.24 ± 0.436) (Fig. 1B). The frequency of C:G to A:T
transversions and C:G to T:A transitions varied inversely with
mutation rate, while the frequency of T:A to C:G transitions
increased with mutation rate.
Ten of the 16 cell lines were derived from cancers of the
tongue, four from the alveolus, one from the buccal mucosa and
one from the hard palate (Fig. 1C; Supplementary Table S1). No
associations were detected between self-described alcohol con-
sumption, tobacco history or age, or between mutation rate or
differentiation status of the primary tumour. However, well-
differentiated tumours tended to have higher mutation rates
than moderately differentiated tumours. All tumours were
negative for common genotypes of human papilloma virus (HPV),
determined by the absence of viral DNA integration in the
sequenced exons.
To identify putative driver genes and pathways that, when
mutated, contribute to OSCC tumourigenesis, the Oncogene-fm
method was applied [21]. We considered signiﬁcant only those
mutated genes or Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways with Q values < 0.10. Only two genes were found
to be signiﬁcantly mutated e the canonical tumour suppressor
TP53 (p-value 1.49  109; q-value 3.72  107) and CSMD2 (CUB
and sushi domain-containing protein 2; p-value 0.00024; q-value
0.03013). While CSMD2 has a tumour suppressive role in several
cancers [23,24], CSMD2 mutations in HNSCC have not been
described previously.
Twenty KEGG pathways were signiﬁcantly mutated across the
16 OSCC lines (Supplementary Table S3). Unsurprisingly, ten were
pathways for speciﬁc cancers and three for other human diseases
proﬁled in KEGG. Three cellular community pathways (Adherens
Junction, Focal Adhesion and Tight Junction) and two signalling
pathways (Wnt and B Cell Receptor Signalling Pathways) were
also signiﬁcantly mutated. Pathway enrichment analysis was
performed in parallel, and seven KEGG pathways were signiﬁ-
cantly mutated with a corrected P value < 0.10 (Supplementary
Table S4). Common pathways identiﬁed by both methods were
Focal Adhesion and Wnt Signalling. The contribution of upregu-
lated Wnt/b-catenin signalling to cell survival and invasion in
HNSCC has been previously discussed [15,25,26]. Recent work
suggests that transcriptional regulation of focal adhesion genes
plays a crucial role in OSCC pathogenesis and that focal adhesion
kinase (FAK) is a key mediator of extracellular matrix interactions
and cellular signalling, contributing to HNSCC onset and pro-
gression [27,28].
In 2015, The Cancer Gene Atlas (TCGA) Network published
genomic proﬁles for 279 HNSCCs [6]. Of the 11 genes identiﬁed in
that study as signiﬁcantly mutated and eight trending towards
signiﬁcance, nine and ﬁve, respectively, were identiﬁed as har-
bouring somatic mutations across 13 of our 16 cell lines (Fig. 1D).
These include inactivating NOTCH1 mutations (found in 10e15% of
HNSCC) [4e6], which cluster to the EGF-like binding domain and
domains necessary for transactivation of target genes. Tumour-
associated NOTCH1 mutations were identiﬁed in three of our
OSCC lines via whole exome sequencing (Fig. 1D). In addition,
Sanger sequencing of the entire genomic region of NOTCH1-3 was
performed on all OSCC lines, including lines for which matched
blood was not available. This identiﬁed several additional novel
bona ﬁde somatic (nonsynonymous, nonsense and indel) mutations(Supplementary Fig. 2). 44% of the cell lines contained mutations in
NOTCH1, many of the mutations clustering in the EGF-like domain.
Mutations in NOTCH2 and 3 were less common. The presence of
mutations in the PEST domain of NOTCH3 could potentially result in
increased receptor activity due to decreased ubiquitin-mediated
degradation.
OSCC lines are representative of primary tumour heterogeneity
To discover whether themutational spectrum of OSCC is distinct
from that of other HNSCCs, we determined the site of origin of each
of 267 tumours in TCGA and then performed unsupervised clus-
tering of the samples according to the signiﬁcance of mutated
KEGG pathways (Fig. 1E). This indicated that the spectrum of KEGG
pathways mutated in OSCC was similar to that of HNSCC arising in
other sites.
To determinewhether the KEGG pathways that weremutated in
the OSCC lines were similar to those in primary tumours, we per-
formed unsupervised clustering of TCGA OSCC samples ranked
according to the frequency of mutated KEGG pathways in the cell
lines. As shown in Fig. 1F, the pathways that were mutated in the
lines were indeed representative of those in primary tumours.
Mutations in CASP8 and FAT1
To evaluate the impact of mutations and expression of puta-
tive driver genes established by genomic studies on OSCC cell
behaviour, we conducted a systematic literature review of genes
implicated in homoeostasis or disease in stratiﬁed squamous
epithelia through regulation of adhesion, invasion or motility. We
focused on genes that were members of multiple mutated non-
tissue speciﬁc KEGG pathways and/or were most signiﬁcantly
mutated in our study and TCGA. We prioritized those genes
harbouring mutations in more than 8% of HNSCCs and at least
two of our cell lines. Seven genes were identiﬁed e PLEC, CASP8,
SYNE2, FAT1, LRP1B, COL11A1 and HUWE1 (Fig. 2A). We also
queried TCGA for pair associations of mutations across these
genes in HNSCC (Fig. 2B). CASP8 and FAT1 (P value ¼ 0.0003), and
SYNE2 and LRP1B (P value ¼ 0.015) were identiﬁed as frequently
co-mutated in HNSCC.
Of the 279 patients with HNSCC reported by TCGA in 2015 [6],
172 patients had tumours of the oral cavity and the other 107 had
tumours of the oropharynx (n ¼ 33), hypopharynx (n ¼ 2) and
larynx (n ¼ 72). Considering copy number alterations and trun-
cating, missense and in-frame mutations, 23% of tumours of the
oral cavity harboured mutations in FAT1 alone, 5.8% in CASP8 alone
and 9.3% in both FAT1 and CASP8, compared with 22%, 2.8% and
1.9%, respectively, in tumours of other areas of the head and neck.
The increased frequency of CASP8 and FAT1 co-mutations in OSCC
relative to other HNSCC, recent evidence suggesting functions of
CASP8 that extend beyond programmed cell death [29], and un-
certainty surrounding the role of FAT1 in oncogenesis [30] led us to
focus on these two genes.
Whole exome sequencing revealed eight putative inactivating
somatic mutations in FAT1 across four of the 16 OSCC lines, and
three in CASP8 across three lines (Fig. 2C). Inactivating mutations
were deﬁned as frameshift indels, and splice-site, nonsense and
missense mutations predicted to be deleterious to protein function
by ANNOVAR. Two lines simultaneously harboured mutations in
both FAT1 and CASP8. Similar to the gene span of inactivating mu-
tations in TCGA, mutations in FAT1 and CASP8 did not localize to any
particular protein domain.
We next determinedmRNA levels of CASP8 and FAT1 in OSCC cell
lines by q-PCR (Fig. 2D). There was no signiﬁcant difference be-
tween CASP8 levels in wild type and mutant lines, nor between
Fig. 2. Identiﬁcation of CASP8 and FAT1 as putative HNSCC/OSCC drivers. A) Genetic alterations in putative driver genes identiﬁed by exome sequencing and literature review.
Samples are arranged to emphasize mutual exclusivity among mutations. Samples without genetic alterations in these genes are not shown. B) Pair associations of genetic al-
terations among putative driver genes in TCGA HNSCC project. P value was determined by Fisher's Exact test. C.O. ¼ co-occurrence, M.E. ¼mutually exclusive. C) Genetic alterations
in CASP8 and FAT1 in TCGA HNSCC and OSCC cell line datasets. LAGD ¼ laminin a-g domain; EGFLR ¼ EGF-like repeat; asterisk indicates mutation present in both TCGA and cell line
datasets. D) mRNA expression of CASP8 and FAT1 in OSCC cell lines. P value was determined by unpaired Student's t-test. *P < 0.01e0.05. No signiﬁcant difference was detected
between presence of CASP8 mutations and CASP8 mRNA expression. OK and CRI-005 are two strains of primary oral keratinocytes. mut ¼ mutant, wt ¼ wild type. E) CASP8 mRNA
levels in tumours with mutant and wild type CASP8 (left hand panel) and FAT1 mRNA levels in tumours with mutant and wild type FAT1 (right hand panel) stratiﬁed by putative
copy-number alterations. Data from TCGA (6).
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Fig. 3. Phenotypic impact of CASP8 and FAT1 mutations and siRNA knockdown in OSCC lines. A) Phase-contrast microscopy of OSCC lines with (mt) and without (wt) predicted
inactivating mutations in FAT1, and effects of FAT1 siRNA on SJG-33 (wt for FAT1). B) FAT1 mRNA expression in OSCC lines plated at low and high density for 48e72 h. OK ¼ primary
oral keratinocytes. C, D) Impact of CASP8 and FAT1 knockdown on clonal growth. (C) Triplicate dishes of SJG-17 cells. (D) Percent well area covered by cell clones. Signiﬁcant
differences from non-targeting control siRNA (siSCR) are shown. AeD) Cells were cultured on feeders. E, F) Impact of CASP8 and FAT1 knockdown on cell migration. (E) Repre-
sentative images of cells at start (0 h) or 24 h later. In high magniﬁcation view, arrow indicates migratory cell front; asterisks indicate individual migrating cells. (F) Migration rate,
deﬁned as fold change in area of central detection zone at 16e24 h. Data are presented as mean ± SEM. (E, F) Cells were plated in the absence of feeders. (D, F) P values were
determined by ANOVA and Tukey's test. *P < 0.01e0.05, **P < 0.001e0.01, ***P < 0.0001e0.001.
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Fig. 4. Impact of CASP8 and FAT1 siRNA knockdown on proliferation, differentiation and apoptosis. A) Proliferationwas assessed by Ki67 immunostaining. Signiﬁcant differences from
non-targeting control siRNA (siSCR) are shown. wt ¼ wild type, mut ¼ mutant, OK ¼ primary oral keratinocytes. B) Terminal differentiation was assessed by transglutaminase 1
(TGM1) immunostaining. A, B) Plasma membranes and nuclei were counterstained with CellMask™ Deep Red and DAPI. C) Cells were incubated with Staurosporine, and apoptosis
was measured by Caspase-3 (CASP3) immunostaining. (AeC) Representative images are shown for SJG-33 (A), control O.K. and SJG-6 (B), siCASP8 and siCASP8/FAT1 SJG-41 (B) and
SJG-17 (C). Data are presented as mean ± SEM. P value was determined by ANOVA and Tukey's test. *P < 0.01e0.05, **P < 0.001e0.01, ***P < 0.0001e0.001. Scale bars 100 mm.
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T.F. Hayes et al. / Cancer Letters 383 (2016) 106e114 113OSCC cells and normal oral keratinocytes. However, there was a
trend for lower FAT1mRNA levels in FAT1mutant lines compared to
wild type (P value < 0.05). In addition, FAT1 mRNA levels were
higher in normal oral keratinocytes than OSCC lines (Fig. 2D). These
observations were consistent with primary tumour data from
TCGA, since CASP8mRNA levels in tumours with mutant CASP8 did
not differ from those with wild type CASP8 at a given copy number,
whereas there was a trend to lower FAT1 mRNA levels in tumours
bearing FAT1 mutations (Fig. 2E).
Phenotypic effects of loss or inactivation of CASP8 and FAT1
To characterise the effect of FAT1 mutations on OSCC lines we
ﬁrst observed themorphology of cells grown on feeders. As shown
in Fig. 3A, cells with FAT1 mutations tended to form less cohesive
colonies than cells that were wild type for FAT1. However, FAT1
knockdown in SJG-33 cells, which are wild type for FAT1, was not
sufﬁcient to reduce cellecell adhesion (Fig. 3A and B). We also
observed that the level of FAT1 mRNA increased with increased
cell density in cells with wild type but not mutant FAT1 (Fig. 3B).
This did not correlate with the level of FAT1 mRNA in cells at low
density and was more marked in OSCC lines than in control oral
keratinocytes.
To determine the impact of FAT1 expression on the growth of
OSCC cells in culture, we performed siRNA-mediated knockdown in
cells with wild type FAT1 (Supplementary Fig. 3A) and then
compared clonal growth with cells expressing scrambled control
siRNA (Fig. 3C and D; Supplementary Fig. 3B). We also examined
cells in which we knocked down CASP8, alone or in combination
with FAT1 knockdown. We observed that knockdown of each gene,
alone or in combination, stimulated clonal growth of OSCC in cul-
ture but had no effect on the growth of primary oral keratinocytes.
Given the association between FAT1 mutation and cellecell
adhesion (Fig. 3A) and between CASP8 and integrin-mediated cell
migration [29], we next examined the effect of knockdown on
cell migration. We monitored the ability of cells to migrate into a
circular area exposed in the centre of the culture dish during a
24 h period. In the case of mutant cells, there were frequent
individual cells that had migrated into the area independently of
the migrating epithelial front (Fig. 3E). Quantitation of the assays
showed that knockdown of FAT1 or CASP8 alone and in combi-
nation increased cell migration in OSCC but not in primary ker-
atinocytes (Fig. 3F). In some cases the effect of CASP8 knockdown
was greater than that of FAT1 (e.g. SJG-8, SJG-32, which harbour
FAT1 mutations), whereas in others knockdown of CASP8 and
FAT1 individually or in combination was equally effective (SJG-6,
SJG-17).
The impact of CASP8 and FAT1 knockdown on clonal growth
could not be accounted for by an increase in proliferation, and in
several cases Ki67 labelling was, rather, reduced (Fig. 4A).
Knockdown of CASP8 and FAT1 did not have a consistent effect on
the proportion of cells that underwent terminal differentiation,
as judged by the percentage of cells expressing Transglutaminase
1: there was no effect of double knockdown on SJG-17 cells;
differentiation was stimulated in SJG-33 cells; and decreased in
SJG-41 cells (Fig. 4B). Knockdown of CASP8 and FAT1 did, how-
ever, increase resistance to Staurosporine-induced apoptosis
(Supplementary Fig. 4), as judged by Caspase-3 immunostaining
(Fig. 4C).
We conclude that loss of function mutations in CASP8 and FAT1
are likely to confer a growth advantage on OSCC by reducing
cellecell adhesion, promoting cell migration and conferring resis-
tance to apoptosis. Furthermore, as expected, knockdown tended to
have more pronounced effects in cells with wild type CASP8 and
FAT1.Discussion
While many investigators have generated cell lines from hu-
man HNSCC and used them to study the biology of this tumour
type [14e16], our study is the ﬁrst to derive cell lines for which
matching normal patient DNA is available. Furthermore, we
demonstrate that the spectrum of tumour-acquired mutations is
representative of that found in tumour biopsies, for example in
the case of NOTCH1-3 [6,15]. These lines will be of considerable
value for studying tumour cell behaviour in vitro and in xenograft
assays.
As proof of the utility of the lines, we studied the impact of loss
of functional CASP8 and FAT1, two genetic changes that, we found,
frequently occur together in individual OSCC. We found that in the
lines, as in primary tumours, inactivating mutations in CASP8 did
not result in a reduction in CASP8 expression, whereas FAT1 mu-
tation did correlate with reduced mRNA levels. While FAT1 mutant
lines showed reduced intercellular adhesion, FAT1 knockdown in a
wild type line was not sufﬁcient to cause a signiﬁcant change in
morphology. It will therefore be of interest to discover whether the
effect of FAT1 loss is dependent on other OSCC mutations (Fig. 1D).
For example, mutations in PTEN will affect the actin cytoskeleton
[31] and AJUBAmutations are likely to impact E-cadherin mediated
cell adhesion [32]. Furthermore, althoughwe have not explored the
underlying mechanism by which FAT1 mRNA levels increase in
some cell lines with increasing cell density but not in others
(Fig. 3B), this has the potential to affect cell behaviour via an impact
on HIPPO signalling [30].
Knockdown of each gene in cells that were wild type for
CASP8 and FAT1 conﬁrmed a clonal growth advantage, consistent
with the observation that CASP8 mutant cells are more aggressive
in tongue xenografts [15]. This could be attributed, at least in
part, to increased cell migration and reduced apoptosis, rather
than to an increase in the proportion of actively cycling cells. The
consequences of stimulation of terminal differentiation, observed
in some cells, remain to be explored but could potentially lead to
increased release of cytokines such as IL-6 that render the
microenvironment permissive for tumour growth [33] and
altered inﬂammatory signalling in CASP8 mutant cells [19]. Cells
that show a more pronounced phenotype on combined knock-
down of CASP8 and FAT1 will be useful for exploring the cancer
relevance of the observed antagonistic interactions between
FAT1 and Caspase 8 [20].
In conclusion, OSCC is highly heterogeneous at both the cellular
and genetic levels. The panel of cell lines that we have characterised
will be useful for identifying the signalling pathways that are
affected by particular combinations of mutations and for discov-
ering how they act both at the level of the cells that bear the mu-
tations and at the level of the surrounding stroma and immune
inﬁltrate. In the long term, this type of approach has the potential to
suggest new combination therapies to improve the outcome for
patients with OSCC.
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